"此次大会以'发展合成生物，培育未来产业'为主题，恰逢其时，意义深远。"中国生物发酵产业协会理 事长于学军说，"我们应聚焦关键，精准发力。一是强化科技创新引领，持续加大投入，鼓励高校、科 研机构与企业携手，开展联合攻关，突破关键技术瓶颈，释放创新活力，提升关键领域的核心竞争力， 让科技创新成为产业发展的强大引擎；二是促进产业协同发展，加强产业链上下游企业间的合作，形成 产业集群效应，推动合成生物学技术在医药、食品、农业、化工、能源等多领域的广泛应用，实现跨产 业的深度融合与协同发展，构建起互利共赢的产业生态；三是加强人才培养与引进，合成生物学作为一 门交叉学科，对复合型人才的需求迫切，应加强高校相关专业建设，完善人才培养体系，同时积极引进 海外高层次人才，为产业发展注入源头活水，提供坚实的人才保障；四是完善政策生态体系，政府部门 需精准施策，制定针对性政策，在税收优惠、财政补贴、项目支持等方面给予产业更多扶持，为合成生 物学产业的茁壮成长创造良好的政策环境，助力产业腾飞。" 本报讯 （记者 闫 利）日前，2025合成生物学技术创新发展大会在江苏宜兴举行。大会以"发展合成生 物 培育未来产业"为主题，8位两院院 ...

特色专场 生物制造青年论坛 8月20日，浙江·宁波 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 SynBioCon 大会 | 生物制造青年论坛 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

《科创板日报》23日讯，今日下午，"2025国际合成生物学产业发展论坛"在上海张江科学会堂举办。市 政府副秘书长夏科家出席并致辞。市科委主任骆大进，张江科学城建设管理办公室主任肖健，上海合成 生物学创新中心理事长金勤献等出席。夏科家表示，上海正抢抓战略机遇、加快布局合成生物学等前沿 科技与未来产业新赛道。面向未来，上海将全力支持合成生物学高质量发展，在政策支持、资金保障、 产品推广、人才引育、开放合作等方面不断强化服务保障，让更多创新成果在上海落地生根、开花结 果。 2025国际合成生物学产业发展论坛在沪举办 ...

Industry Overview - Synthetic biology has gained significant attention from both the scientific and investment communities, with increasing research and application prospects across various fields [1][2] - The global synthetic biology market was approximately $12.2 billion in 2022, showing a year-on-year growth of 28.42%, and is projected to reach $15.1 billion in 2023 and $19 billion in 2024, with a forecast of $24.3 billion by 2025 [1] - Major countries, including the US, UK, EU, and China, are intensifying their strategic investments and policy support in synthetic biology, positioning it as a strategic high ground in future global competition [1][3] Company Developments - Haizheng Pharmaceutical has established a joint venture, Lian Sheng Synthetic, with a registered capital of 350 million yuan, aiming to enter the synthetic biology sector [2] - Shenghe Biotechnology has launched China's first production line for natural product biosynthesis, which will serve various industries including cosmetics and pharmaceuticals [2] - Lian Sheng Synthetic is set to invest 170 million yuan in a flexible production line for synthetic biology, with its first product expected to be launched in August [5] Market Dynamics - The economic value of synthetic biology and bio-manufacturing is projected to reach $100 billion by 2025, with an expectation that 60% of material production will be achieved through bio-manufacturing methods [5] - The industry is characterized by a competitive landscape where companies are striving to convert midstream technologies into marketable products, emphasizing the importance of industrialization capabilities [5][9] Challenges and Opportunities - The transition from laboratory to commercial application in synthetic biology faces multiple challenges, including technical feasibility, engineering conversion, and market adaptability [7][8] - The industry is experiencing a "valley of death" in industrialization, where many promising technologies fail to scale up due to the lack of pilot testing [8] - Despite the challenges, the integration of AI and machine learning is expected to enhance research capabilities and support the development of synthetic biology [6] Strategic Insights - The current landscape indicates a need for innovation to avoid price competition and to develop high-value products that can lead the market [9] - The establishment of supportive policies at the provincial and national levels in China is anticipated to further guide and promote the healthy development of the synthetic biology industry [6]

Core Insights - A significant breakthrough in genomics has been achieved by a team from Yale University, enhancing the ability to edit multiple DNA sites within the same cell by twofold while reducing unintended mutations in nearby gene sites [1][2] - The new technology allows for simultaneous modifications across different sections of the DNA, akin to editing multiple chapters in a vast manuscript of 3 billion characters, rather than just individual words on the same page [1] Group 1 - The research team utilized CRISPR-associated protein Cas12, which has a natural ability to handle multiple guide RNAs (gRNAs), to improve editing precision [1] - By optimizing gRNAs, including shortening their length and adjusting RNA base composition, the team significantly increased the number of edits possible within a single cell [1] - The team successfully achieved simultaneous editing of 15 different gene sites in human cells, tripling the previous capabilities of existing systems [1] Group 2 - This breakthrough is expected to aid in the understanding of complex genetic diseases such as cancer and will support the design of synthetic genomes and the development of new therapeutic drugs [2] - The research addresses key obstacles in mammalian genome editing, which is crucial for studying single nucleotide variant-related diseases and constructing synthetic mammalian genomes [2] Group 3 - The advancement lays a solid foundation for the future of precision medicine and synthetic biology [3] - Gene editing technology, often referred to as "molecular scissors," allows scientists to cut and insert specific DNA segments, making it a simple and cost-effective tool in life sciences [3] - Continuous iterations and upgrades in gene editing technology aim to enhance efficiency and precision, transitioning from "molecular scissors" to "molecular scalpels" for more significant applications in precision medicine and modern agriculture [3]

SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

精英计划-人才需求 | 天津工生所 中国科学院天津工业生物技术研究所是由中国科学院与天津市人民政府共建、整建制从事生物制造和 工业生物技术研究的国立科研机构，是我国工业生物领域的战略科技力量，肩负着创新生物产业关键 核心技术、发展生物制造重大颠覆性技术、支撑我国生物经济高质量可持续发展的历史使命，围 绕"以可再生碳资源替代化石资源、以清洁生物加工方式替代传统化学加工方式、以现代生物技术提 升产业水平"三大战略主题，重点开展"工业蛋白质科学与生物催化工程、合成生物学与微生物制造 工程、生物系统与生物工艺工程"三个领域方向的基础研究和应用基础研究。 招 聘部门 简介 01 邓子新大师工作室以活性天然产物的创新与绿色制造为目标，遵循"师从于自然、认知于自然，创新 于自然"的学术思路，运用合成生物学理念，聚焦交叉学科前沿，建立和完善天然药物精准发掘、结 构创新和优产新模式，实现微生物天然药物的高效生产。 团队由 徐敏研究员 与 侯安伟研究员 领衔，重点关注全新作用机制抗生素（糖肽抗生素）与萜类天 然产物的高效精准挖掘、生物合成机制与作用机制解析以及相关新分子的高效创制。 徐敏研究员主要从事微生物天然产物合成生物学以及 ...

【SynBioCon】 获 悉， 6月19日电， 海正药业 公告称其拟与全资子公司瀚晖制药之香港全资子公司 辉正国际合资 设立 合成生物 学独立子公司 ，注册资本 3.5亿元 。新公 司名为 浙江沄生合成生物科 技有限公司 （简称 沄生合成 ）。 海正药业 拟认缴出资2.6亿元，占74.29%，辉正国际拟认缴出资0.9亿元，占注册资本的25.71%。公 告显示，该合资公司将整合资源，结合辉正国际在香港的平台优势，为公司 合成生物 学业务的专业 化、规模化发展提供有力支撑。 资本事件 | 海正药业 海正药业成立于1956年，2000年海正在上海证券交易所上市。公司目前市值超百亿，是国内重要的原 料药生产企业，其产品涵盖多个治疗领域，包括抗肿瘤、心血管系统、抗感染等。 2024年前三季度，公司营收为78.75亿元，归母净利润为5.15亿元。随着肖卫红出任公司董事长，公 司将合成生物视为除人用药、动物药之外的新兴业务。 携手浙工大，加快合成生物项目落地 自2024年11月， 海正药业携手 浙江工业大学 共建 合成生物制造创新研究院 ，双方合作有望加速合 成生物学技术从前端研发到产业化落地的进程。 未来公司将基于合成 ...

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. reported a significant increase in overseas revenue for 2024, driven primarily by growth in amino acid product sales and the introduction of new products [2][19]. Group 1: Overseas Revenue Performance - The company achieved overseas revenue of 1.032 billion yuan in 2024, accounting for 47.39% of total revenue, representing a year-on-year growth of 30.34% [2][19]. - The breakdown of overseas revenue shows that the main business revenue increased by 30.34% to 1.032 billion yuan, while other business revenue rose by 88.86% to 40.65 million yuan [2][5]. - The primary regions for overseas sales include Europe, America, and Asia, with varying gross profit margins due to differences in product structure [5][19]. Group 2: Audit Procedures and Findings - The annual audit firm conducted thorough procedures to verify the authenticity and accuracy of overseas revenue, including internal control evaluations and document checks [7][8]. - The audit confirmed that 74.73% of overseas revenue was verified through customer confirmations, indicating a high level of reliability in reported figures [9][21]. - The audit also matched overseas sales data with third-party data, such as export tax refund claims and foreign exchange management bureau data, revealing minimal discrepancies [11][12]. Group 3: Gross Margin Analysis - The company's overall gross margin for 2024 was reported at 24.92%, a decline of 15.60 percentage points from the previous year, primarily due to decreased margins in amino acid and vitamin products [21][22]. - The average selling prices for amino acids and vitamins fell significantly, with L-valine prices dropping by 17.89% and vitamin prices by 54.09% [23][24]. - The decline in gross margins is attributed to increased competition and market dynamics, with the company implementing measures to address these challenges [27][35]. Group 4: Future Outlook and Industry Trends - The demand for amino acids is expected to grow due to trends in precision nutrition and reduced reliance on traditional feed ingredients, which may positively impact future margins [27][29]. - The global market for biosynthetic vitamins is projected to grow significantly, indicating potential opportunities for the company as it expands its product offerings [29][30]. - The company is positioned to benefit from technological advancements in production processes, which may enhance cost efficiency and product competitiveness in the long term [31][32].

Core Viewpoint - The company reported a significant increase in overseas revenue for 2024, driven primarily by the growth in amino acid product sales and the introduction of new products, despite a decline in overall gross margin due to competitive pricing pressures in the market [2][18]. Group 1: Overseas Revenue Performance - The company achieved overseas revenue of 1.032 billion yuan in 2024, accounting for 47.39% of total revenue, representing a year-on-year growth of 30.34% [2][3]. - The main contributors to the overseas revenue growth were the amino acid series products, particularly L-valine, and the vitamin series products, which saw increased sales volumes [5][18]. - The company’s overseas sales were primarily concentrated in Europe (41.58%), the Americas (28.51%), and Asia & others (29.91%) [3][4]. Group 2: Gross Margin Analysis - The overall gross margin for the company in 2024 was reported at 24.92%, a decrease of 15.60 percentage points compared to the previous year [18]. - The gross margin for amino acid products was 30.00%, down 13.32 percentage points, while the vitamin products experienced a more significant decline [18][19]. - The decline in gross margin was attributed to lower average selling prices for key products such as L-valine and myo-inositol, which saw price drops of 17.89% and 54.09% respectively [19][20]. Group 3: Future Outlook and Industry Trends - The demand for amino acids is expected to continue growing due to trends in precision nutrition and the reduction of traditional feed ingredients like soybean meal [23][24]. - The global market for biosynthetic vitamins is projected to grow significantly, with a compound annual growth rate of 9.32% from 2024 to 2030, driven by advancements in synthetic biology [24]. - The company is positioned to benefit from its technological advantages in fermentation processes, which are more environmentally friendly and cost-effective compared to traditional methods [27][28].